Nurullah İlhan,MD· @drnurullahilhan · X·· 18 hours agoScore70
Body · original
#NATALEE at 6 years: sustained iDFS benefit with adjuvant ribociclib.
iDFS: 83.2% vs 77.9%.
OS favored ribociclib; nominal significance only, with descriptive analysis outside formal testing.
Assoc. Prof. Nurullah İlhan
#ESMO2026 #BreastCancer #OncoTwitter
25 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Nurullah İlhan,MD · x.com